Caris Life Sciences
117 hedge funds and large institutions have $2.92B invested in Caris Life Sciences in 2025 Q2 according to their latest regulatory filings, with 117 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
38.56% more ownership
Funds ownership: 0% → 38.56% (+39%)
99% less call options, than puts
Call options by funds: $26K | Put options by funds: $2.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sixth Street Partners
Dallas,
Texas
|
+$657M |
| 2 |
Coatue Management
New York
|
+$273M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$233M |
| 4 |
Braidwell
Stamford,
Connecticut
|
+$197M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$197M |
Top Sellers
CAI Hedge Fund Activity: Q2 2025 in Review
117 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Caris Life Sciences (CAI) for Q2 2025, worth a combined $2.92B.
Buyers outnumbered sellers: 117 funds opened new CAI positions and 0 closed out — a net gain of 117 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sixth Street Partners, opening a new position worth an estimated $657M.
- 117 institutional investors held Caris Life Sciences (CAI) as of Q2 2025, up from 0 in Q1 2025.
- Funds reported $2.92B of Caris Life Sciences stock for Q2 2025.
- 117 funds opened new Caris Life Sciences positions in Q2 2025 and 0 closed out, a net change of +117 holders.
- The largest Caris Life Sciences buyer in Q2 2025 was Sixth Street Partners, an estimated $657M added.
Based on aggregated 13F filings for Q2 2025.